Background & AimsWe compared outcomes by cirrhosis status across studies of the all-oral combination of daclatasvir (DCV) plus asunaprevir (ASV). ;MethodsOutcomes from global and Japanese phase 2 and 3 clinical studies of DCV+ASV in patients with genotype (GT) 1b infection were assessed by cirrhosis status. Sustained virological response (SVR) was assessed in individual phase 3 studies; a pooled analysis was carried out for safety outcomes. ;ResultsIn the Japanese phase 3 study, SVR12 was achieved by 91% of patients with cirrhosis (n = 22) and 84% of patients without cirrhosis (n = 200); in the global phase 3 study, SVR12 was achieved by 84% of patients with cirrhosis (n = 206) and by 85% of patients without cirrhosis (n = 437). The frequen...
We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in p...
International audienceBACKGROUND: A few direct antiviral agents have been studied in difficult-to-tr...
UNLABELLED: Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanc...
Background: The efficacy and safety of asunaprevir + daclatasvir combination therapy for treatment o...
International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatmen...
BACKGROUND & AIMS: Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activi...
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and...
BACKGROUND AND AIM: This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all...
IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens req...
AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for...
All-oral combinations of direct-acting antivirals may improve efficacy and safety out-comes for pati...
Background & Aims: Improved therapies for peginterferon/ribavirin null or partial responders are nee...
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent...
Background & AimsThe combination of peginterferon and ribavirin with telaprevir or boceprevir is the...
Background: Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1...
We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in p...
International audienceBACKGROUND: A few direct antiviral agents have been studied in difficult-to-tr...
UNLABELLED: Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanc...
Background: The efficacy and safety of asunaprevir + daclatasvir combination therapy for treatment o...
International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatmen...
BACKGROUND & AIMS: Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activi...
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and...
BACKGROUND AND AIM: This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all...
IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens req...
AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for...
All-oral combinations of direct-acting antivirals may improve efficacy and safety out-comes for pati...
Background & Aims: Improved therapies for peginterferon/ribavirin null or partial responders are nee...
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent...
Background & AimsThe combination of peginterferon and ribavirin with telaprevir or boceprevir is the...
Background: Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1...
We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in p...
International audienceBACKGROUND: A few direct antiviral agents have been studied in difficult-to-tr...
UNLABELLED: Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanc...